EVIA Life Sciences Inc. — SEC Form D Filing

EVIA Life Sciences Inc. filed an SEC Form D on November 2, 2026, reporting $700K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
November 2, 2026
Amount reported
$700K
Round stage
Seed stage based on raising $700,002 to scale early commercial manufacturing of its novel formulation portfolio.
Industry
Biotechnology
Website
https://evialifesciences.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional cell cryopreservation relies on toxic dimethyl sulfoxide, which compromises post-thaw cell viability and presents health risks for cell therapy patients.

Solution

EVIA Life Sciences produces non-DMSO cryopreservation solutions utilizing natural organic compounds to maintain cell viability and safety for cell therapy and reproductive medicine.

Why now

The rapid clinical adoption of advanced cell therapies requires non-toxic biopreservation media to eliminate toxic washing steps and meet stricter regulatory standards.

Source: SEC EDGAR Form D filing